Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 7, 2015, Pages 2145-2150

  Feng, Mingye ^a,b,c   Chen, James Y ^a,b,c   Weissman Tsukamoto, Rachel ^a,b,c   Volkmer, Jens Peter ^a,b,c   Ho, Po Yi ^a,b,c   McKenna, Kelly M ^a,b,c   Cheshier, Samuel ^a   Zhang, Michael ^a   Guo, Nan ^a,b,c   Gip, Phung ^a,b,c   Mitra, Siddhartha S ^a   Weissman, Irving L ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ludwig Center for Cancer Stem Cell Research and Medicine   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CALRETICULIN; CD47 ANTIGEN; TOLL LIKE RECEPTOR; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CANCER CELL; CANCER CELL LINE; CELL SURFACE; COLON CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TARGET CELL; ENZYMOLOGY; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

CALRETICULIN; HUMANS; MACROPHAGES; NEOPLASMS; PROTEIN-TYROSINE KINASES; TOLL-LIKE RECEPTORS;

EID: 84923166595     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1424907112     Document Type: Article

References (45)

1. Chao MP, Majeti R, Weissman IL (2012) Programmed cell removal: A new obstacle in the road to developing cancer. Nat Rev Cancer 12(1):58-67.
2. Lagasse E, Weissman IL (1994) bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 179(3):1047-1052.
3. Jaiswal S, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271-285.
4. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-299.
5. Chao MP, et al. (2011) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118(18):4890-4901.
6. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109(17):6662-6667.
7. Chao MP, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71(4):1374-1384.
8. Chao MP, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699-713.
9. Edris B, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109(17):6656-6661.
10. Kim D, et al. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26(12):2538-2545.
11. Chao MP, et al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2(63):63ra94.
12. Gardai SJ, et al. (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123(2):321-334.
13. Ogden CA, et al. (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194(6):781-795.
14. Rawlings DJ, Witte ON (1994) Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol Rev 138:105-119.
15. Mohamed AJ, et al. (2009) Bruton's tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228(1):58-73.
16. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9(6):722-728.
17. Good RA, Varco RL (1955) A clinical and experimental study of agammaglobulinemia. J Lancet 75(6):245-271.
18. Tsukada S, Witte ON (1994) X-linked agammaglobulinemia and Bruton's tyrosine kinase. Adv Exp Med Biol 365:233-238.
19. Amoras AL, Kanegane H, Miyawaki T, Vilela MM (2003) Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J Investig Allergol Clin Immunol 13(3):181-188.
20. O'Neill LA, Golenbock D, Bowie AG (2013) The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 13(6):453-460.
21. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13(5):816-825.
22. Guha M (2012) Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 11(7): 503-505.
23. Ní Gabhann J, Jefferies CA (2011) TLR-induced activation of Btk-role for endosomal MHC class II molecules revealed. Cell Res 21(7):998-1001.
24. Lim KH, Staudt LM (2013) Toll-like receptor signaling. Cold Spring Harb Perspect Biol 5(1):a011247.
25. Doyle SL, Jefferies CA, Feighery C, O'Neill LA (2007) Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem 282(51):36953-36960.
26. Schmidt NW, Thieu VT, Mann BA, Ahyi AN, Kaplan MH (2006) Bruton's tyrosine kinase is required for TLR-induced IL-10 production. J Immunol 177(10):7203-7210.
27. Lee KG, et al. (2012) Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response. Proc Natl Acad Sci USA 109(15):5791-5796.
28. Fukao T, Koyasu S (2003) PI3K and negative regulation of TLR signaling. Trends Immunol 24(7):358-363.
29. Jabir MS, et al. (2014) Caspase-1 cleavage of the TLR adaptor TRIF inhibits autophagy and β-interferon production during Pseudomonas aeruginosa infection. Cell Host Microbe 15(2):214-227.
30. Burger JA, Buggy JJ (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385-2391.
31. Brown JR (2013) Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep 8(1):1-6.
32. Yang W, Desiderio S (1997) BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci USA 94(2):604-609.
33. Mahajan S, et al. (2001) Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 276(33):31216-31228.
34. Kurosaki T, et al. (2000) Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev 176:19-29.
35. Byrne JC, et al. (2013) Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin. J Immunol 190(10): 5207-5215.
36. Vandivier RW, et al. (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: Calreticulin and CD91 as a common collectin receptor complex. J Immunol 169(7):3978-3986.
37. Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9:216.
38. Mori K, Hiroi M, Shimada J, Ohmori Y (2011) Infiltration of m2 tumor-associated macrophages in oral squamous cell carcinoma correlates with tumor malignancy. Cancers (Basel) 3(4):3726-3739.
39. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
40. Jaiswal S, Chao MP, Majeti R, Weissman IL (2010) Macrophages as mediators of tumor immunosurveillance. Trends Immunol 31(6):212-219.
41. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271.
42. Tseng D, et al. (2013) Anti-CD47 antibody-mediated phagocytosis of cancer bymacrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 110(27):11103-11108.
43. Oldenborg PA, et al. (2000) Role of CD47 as a marker of self on red blood cells. Science 288(5473):2051-2054.
44. Theocharides AP, et al. (2012) Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 209(10):1883-1899.
45. Sanjana NE, et al. (2012) A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7(1):171-192.